Following this transaction Malcolm Lloyd-Smith’s holding in the company was increased by 74.89% to a total of $1.66 million. In addition to Malcolm Lloyd-Smith, one other NBIX executive reported Buy trades in the last month.
Based on Neurocrine’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $152 million and quarterly net profit of $50.76 million. In comparison, last year the company earned revenue of $60.77 million and had a GAAP net loss of $11.13 million. NBIX’s market cap is $9.84B and the company has a P/E ratio of 1994.49. Currently, Neurocrine has an average volume of 569.6K.
Starting in November 2017, NBIX received 66 Buy ratings in a row. Based on 9 analyst ratings, the analyst consensus is Strong Buy with an average price target of $134.56, reflecting a 24.2% upside. Nine different firms, including Jefferies and Cantor Fitzgerald, currently also have a Buy rating on the stock.
The insider sentiment on Neurocrine has been positive according to 59 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Neurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders.